Jackson Square Capital’s Cellebrite CLBT Stock Holding History

Jackson Square Capital’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-72,456	Closed	-$1.6M	–	142
2024 Q4	$1.6M	Buy	+72,456	New	+$1.39M	0.38%	55

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jackson Square Capital's CLBT Position: Q1 2025 in Review

Jackson Square Capital sold out of Cellebrite (CLBT) in Q1 2025, closing a stake of 72,456 shares — an estimated $1.6M sold.

Jackson Square Capital first reported a position in CLBT in Q4 2024 and held it in 1 quarter. The position peaked at $1.6M in Q4 2024. 199 funds tracked by Wall St. Rank hold CLBT as of Q1 2025.

Jackson Square Capital reported no remaining Cellebrite position as of Q1 2025 after selling out during the quarter.
Jackson Square Capital sold 72,456 Cellebrite shares in Q1 2025, an estimated $1.6M.
Jackson Square Capital first reported a position in Cellebrite in Q4 2024 and held it in 1 quarter.
Jackson Square Capital's Cellebrite position peaked at $1.6M in Q4 2024.
199 funds tracked by Wall St. Rank held Cellebrite as of Q1 2025.

Based on Jackson Square Capital's 13F filing for Q1 2025, filed 16 Apr 2025.